Erenumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Erenumab and local guidelines before prescribing.
CGRP antagonist
Mechanism
CGRP receptor monoclonal antibody.
Uses
Migraine prophylaxis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Constipation, hypertension, injection-site reactions.
Interactions
Few.
Contraindications and cautions
Uncontrolled hypertension
Monitoring
BP
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Monitor BP; constipation can be severe.
More from the textbook: uses, cautions and other points
- Side effects: constipation (erenumab), injection-site reactions.
Neurology: Headache and Facial Pain - CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and atogepant or rimegepant - after 3 preventive drugs have failed (NICE TAs; specialist).
Neurology: Anatomy, Physiology and Pharmacology - Erenumab / fremanezumab / galcanezumab / eptinezumab | CGRP antibodies after 3 preventives fail; review at 12 weeks.
Neurology: Headache and Facial Pain
Where it is discussed in the book
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Headache and Facial Pain (2 mentions)